Last reviewed 2026-05-17 · How we verify

Burgodin (BEZITRAMIDE)

Phase 2 active Small molecule

Burgodin (generic name: BEZITRAMIDE) is a bezitramide drug. It is currently in Phase 2 development.

Burgodin works by modulating ion channels in the body.

Burgodin, also known as bezitramide, is a small molecule drug of the bezitramide class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating certain ion channels in the body. Burgodin's commercial status and approved indications are unclear, and it is not known whether it is patented or available as a generic medication. Further research is needed to fully understand its effects and potential uses. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unknown.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BEZITRAMIDE
Drug class	bezitramide
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of ion channels like gates that control the flow of tiny particles called ions in and out of cells. When these gates are open or closed, it can affect how cells work and communicate with each other. Burgodin is thought to affect the way these gates work, but the exact details of how it does this are still unclear.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Burgodin CI brief — competitive landscape report
Burgodin updates RSS · CI watch RSS

Frequently asked questions about Burgodin

What is Burgodin?

Burgodin (BEZITRAMIDE) is a bezitramide drug.

How does Burgodin work?

Burgodin works by modulating ion channels in the body.

What is the generic name of Burgodin?

BEZITRAMIDE is the generic (nonproprietary) name of Burgodin.

What drug class is Burgodin in?

Burgodin belongs to the bezitramide class. See all bezitramide drugs at /class/bezitramide.

What development phase is Burgodin in?

Burgodin is in Phase 2.

Drug class: All bezitramide drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing